New Therapeutic Strategies for Hodgkin Lymphoma in Cooperation of Radiation Oncology and Medical Oncology;Neue Therapiestrategien des Morbus Hodgkin in Kooperation von Radioonkologie und Internistischer Onkologie

Rontgenpraxis

Volumn 55, Issue 3, 2003, Pages 114-124

  Eich, Hans Theodor ^a   Müller, Rolf Peter ^a   Ansén, Sascha ^a   Josting, Andreas ^a   Engert, Andreas ^a   Hansemann, Katja ^a   Pfistner, Beate ^a   Wolf, Jürgen ^a   Willich, Normann ^b   Diehl, Volker ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Chemotherapy; Combined Modality Therapy; Hodgkin's disease; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; GERMANY; HODGKIN DISEASE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT CARE TEAM; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 11144355261     PISSN: 00357820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bates NP, Williams MV, Bessel EM, Vaughan Hudson G, Vaughan Hudson B (1994) Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: A British National Lymphoma Investigation pilot study. J Clin Oncol 12: 288-296
2. Battmann A, Dieckmann K, Battmann A, Resch A, Pötter R (2001) Mediastinal Hodgkin lymphomas in computertomography: exact CT-based volume assessment and approximations with simple geometric models. Strahlenther Onkol 3: 132-137
3. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975) Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboximide versus MOPP. Cancer 36: 252-259
4. Canellos GP, Anderson JR, Propert KJ, et al. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 327:1478-1484
5. Carde P, Hagenbeek A, Hayat M, et al. (1993) Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early stage Hodgkin's disease. The H6 randomised trials from the European Organisation for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11: 2258-2272
6. Connors JM, Klimo P, Adams G, et al. (1997) Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15: 1638-1645
7. Diehl V, Sieber M, Rüffer U, et al. (1997) BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 8: 143-148
8. Diehl V, Tesch H, Lathan B et al. (1997) BEACOPP, a new intensified hybrid regimen, is at least equally effective compared with COPP/ABVD in patients with advanced stage Hodgkin's lymphoma. Proc Am Soc Clin Oncol 16: Abstr. 5
9. Dörr W, Herrmann T (2002) Second primary tumors after radiotherapy for malignancies. Strahlenther Onkol 7: 357-362
10. Dühmke E, Diehl V, Löffler M, et al. (1996) Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 36: 305-310
11. Duggan D, Petroni G, Johnson J, et al. (1997) MOPP/ABV versus ABVD for advanced Hodgkin's disease-preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC). Proc Am Soc Clin Oncol 16: Abstr. 43
12. Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep 63: 1727-1733
13. Hagenbeek A, Carde P, Noordijk E, et al. 1997) Prognostic factor tailored treatment of early stage Hodgkin's disease. Results from a prospective randomized phase III clinical trial in 762 patients (H7 study). Blood 90 (supplement 1): Abstr. 2603
14. Henry-Amar M (1992) Second cancer after the treatment for Hodgkin's disease: A report from the International Database on Hodgkin's disease. Ann Oncol 3:117-128
15. Homing SJ, Hoppe RT, Hancock SL, Rosenberg SA (1988) Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 6: 1822-1831
16. Kaplan HS (1966) Role of intensive radiotherapy in the management of Hodgkin's disease. Cancer 19: 356-362
17. Lang O, Bihl H, Hültenschmidt B, Sautter-Bihl M-L (2000) Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease. Strahlenther Onkol 3: 138-144
18. LENT SOMA scales for all anatomic sites (1995). Int J Radiat Oncol Biol Phys 31: 1049-1091
19. Löffler M, Brosteanu O, Hasenclever D, et al. (1998) Meta-Analysis of Chemotherapy versus combined modality treatment trials in Hodgkin's Disease. J Clin Oncol 6: 818-829
20. Longo DL, Young RC, Wesley M, et al. (1986) Twenty years of MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 4: 1295-1306
21. Pavy JJ, Denekamp J, Letschert et al. (1995) Late effects toxicity scoring: The SOMA scale. Int J Radiat Oncol Biol Phys 31: 1043-1047
22. Radford JA, Cowan RA, Ryder WDJ (1996) Four weeks of neo-adjuvant chemotherapy significantly reduces the progression rate in patients treated with limited field radiotherapy for clinical stage (CS) IA/IIA Hodgkin's disease. Results of a randomised pilot study. Ann Oncol 7: Abstr. 66
23. Santoro A, Bonfante V, Viviani S et al. (1996) Subtotal nodal (STNI) vs. involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin's disease. Proc Am Soc Clin Oncol 15: Abstr. 1271
24. Sieber M, Rüffer U, Tesch H et al. (1997) Rapidly Alternating COPP+ ABV+IMEP (CAI) is Equally Effective as Alternating COPP+ABVD (CA) for Hodgkin's Disease: Final Results of Two Randomized Trials For Intermediate (HD5 protocol) And Advanced (HD6 protocol) stages. American Society of Hematology. Thirty-Ninth Annual Meeting. Blood 90 (Suppl. 1): Abstr. 2605
25. Sieber M, Franklin J, Bredenfeld H, et al. (2001) Promising results with a 14 day variant of the BEACOPP regimen in advanced stage Hodgkin's lymphoma (HL): A pilot-study of the German Hodgkin Lymphoma Study Group (GHSG). BLOOD 98, 11, Suppl. 3203A
26. Specht L, Gray, ML, Clarke MJ, Peto R (1998) Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 16: 830-843
27. Staar S, Müller R-P, Diehl V, Eich HT, Engert A, Roehl M (2001) The value of prospective radiotherapy treatment planning in the multicentric German Hodgkin's Lymphoma Study Group. Int J Radiat Biol Phys 51 (3) (Suppl 1): 70
28. Trümper L, Pfreundschuh M (2000) The role of treatment duration in chemotherapy regimens for the treatment of malignant diseases. Strahlenther Onkol 176: 466-471
29. Viviani S, Bonadonna G, Santoro A, et al. (1996) Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's Disease: Ten-year results. J Clin Oncol 14: 1421-1430
30. Zittoun R, Audebert A, Hoerni B, et al. (1985) Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol 3: 207-214